

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Allenspach, C.)	GROUP ART UNIT:	1616
)		
SERIAL NO.:	10/647,501)	CONFIRMATION NO.:	2375
)		
EXAMINER:	Arnold, Ernst V.)	ATTORNEY DOCKET	PC27523
)	NO.:	(1139/3/US)
FILED:	08/25/2003)		
TITLE:	PHARMACEUTICAL COMPOSITION EXHIBITING CONSISTENT DRUG RELEASE PROFILE			

January 7, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO NOTICE OF NON-COMPLIANT AMENDMENT

In response to the Notice of Non-Compliant Amendment Under 37 CFR 1.121 dated October 26, 2007, attached is a revised version of the amendments to the claims with the status identifiers.

A two month extension of time is hereby requested. Please charge any appropriate fees to Deposit Account No 16-1445

Respectfully submitted,



Philip B. Polster II
Attorney for Applicants
Reg. No. 43,864
Pfizer, Inc.
Corporate Patent Law Department
314-274-9094 (St. Louis)

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Allenspach, C.)	GROUP ART UNIT:	1616
)		
SERIAL NO.:	10/647,501)	CONFIRMATION NO.:	2375
)		
EXAMINER:	Arnold, Ernst V.)	ATTORNEY DOCKET	PC27523
)	NO.:	(1139/3/US)
FILED:	08/25/2003)		
TITLE:	PHARMACEUTICAL COMPOSITION EXHIBITING CONSISTENT DRUG RELEASE PROFILE			

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO OFFICE ACTION (Revised)

This paper is in response to the Office Action dated April 16, 2007, having a three month Shortened Statutory Period for Reply that is set to expire on July 16, 2007. A three month extension of time, up to and including October 16, 2007 is hereby requested. Because the last Office Action was made final, a Request for Continued Examination (RCE) is filed with this amendment. Please charge any appropriate fees for the making of this amendment to Deposit Account No 16-1445



January 7, 2008

Philip B. Polster II
Reg. No. 43,864

The Listing of Claims begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper